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Background. Vitamin D deﬁciency is associated with impaired immune responses and increased susceptibility
to a number of intracellular pathogens in individuals infected with human immunodeﬁciency virus (HIV). It is not
known whether such an association exists with Cryptococcus neoformans.
Methods. Levels of 25-hydroxyvitamin D (25[OH]D) were measured in 150 patients with cryptococcal menin-
gitis (CM) and 150 HIV-infected controls in Cape Town, South Africa, and associations between vitamin D deﬁ-
ciency and CM were examined. The 25-hydroxyvitamin D levels and cryptococcal notiﬁcations were analyzed for
evidence of reciprocal seasonality. Associations between 25(OH)D levels and disease severity, immune responses,
and microbiological clearance were investigated in the patients with CM.
Results. Vitamin D deﬁciency (plasma 25[OH]D≤50 nmol/L) was present in 74% of patients. Vitamin D deﬁciency
was not associated with CM (adjusted odds ratio, 0.93 [95% conﬁdence interval, .6–1.6]; P = .796). Levels of 25(OH)D
showed marked seasonality, but no reciprocal seasonality was seen in CM notiﬁcations. No signiﬁcant associations were
found between 25(OH)D levels and fungal burden or levels of tumor necrosis factor α, interferon γ, interleukin 6, soluble
CD14, or neopterin in cerebrospinal ﬂuid. Rates of fungal clearance did not vary according to vitamin D status.
Conclusions. Vitamin D deﬁciency does not predispose to the development of CM, or lead to impaired immune
responses or microbiological clearance in HIV-infected patients with CM.
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Cryptococcal meningitis (CM) is a leading cause
of death in human immunodeﬁciency virus (HIV)–
infected individuals in low-resource settings [1]. The
causative organism, Cryptococcus neoformans, is a fac-
ultative intracellular pathogen that has developed nu-
merous strategies allowing it to survive and replicate
inside macrophages [2, 3]. Environmental exposure to
Cryptococcus is universal [4]. In the context of impaired
adaptive immune responses, the ability of Cryptococcus
to evade macrophage killing leads to dissemination, dis-
ease, and ultimately death [5]. Although the primary
immune defect leading to development of cryptococcal
meningitis is impairment of CD4+ T-cell (CD4) re-
sponses, usually secondary to HIV infection [6], the
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effectiveness of macrophage recognition, processing, and killing
of Cryptococcus is likely to play an important role in the evolu-
tion of infection [2, 3, 7].
Vitamin D is required for effective macrophage responses to a
number of intracellular pathogens including Mycobacterium
tuberculosis complex (MTB), where it plays a critical role in mac-
rophage activation following Toll-like receptor (TLR) signaling,
tumor necrosis factor alpha (TNF-α) release, interferon gamma
(IFN-γ)–mediated cathelicidin function, phagolysosome matura-
tion and autophagy, and intracellular killing of mycobacteria [8–
13]. Macrophages from HIV-infected patients have particularly
impaired antituberculous activity in the absence of adequate vi-
tamin D levels [8,14],consistent with themarkedly increased sus-
ceptibility to tuberculosis during HIV infection [15].
Similar to tuberculosis, CM is caused by an inhaled pathogen
that evades effective intracellular killing by alveolar macrophag-
es, often establishes a latent infection in the lung, and dissem-
inates and causes disease when effective T-cell–mediated
immune responses are depleted in HIV infection [5]. Data
show that HIV-infected patients who have had pulmonary tu-
berculosis are at increased risk of developing CM [16], raising
the possibility of a shared immune defect over and above
CD4+ T-cell depletion. We hypothesized that vitamin D deﬁ-
ciency may impair immune responses to Cryptococcus, leading
to similar increases in susceptibility to disease and impairments
of microbiological clearance to those seen in MTB infection.
To test this hypothesis, we performed a study in Cape Town,
South Africa, consisting of 3 parts: (1) 25-hydroxyvitamin D
(25[OH]D) levels were measured in patients presenting with
CM and control patients with comparable CD4 counts drawn
from the same population who did not have CM to determine
whether vitamin D deﬁciency was associated with the develop-
ment of CM; (2) 25(OH)D levels in the study population were
analyzed for evidence of seasonality corresponding to sunshine
hours, and Western Cape CM notiﬁcations from the South Af-
rican National Institute for Communicable Diseases (NICD)
covering the study period were analyzed for evidence of recip-
rocal seasonality; and (3) associations between 25(OH)D levels
and disease severity, immune responses, and microbiological
clearance rates were examined in patients with CM.
METHODS
Participants and Procedures
Participants were recruited at GF Jooste Hospital, Cape Town,
South Africa, between July 2005 and May 2010. One hundred
ﬁfty participants were HIV-infected adults (aged ≥21 years)
with a ﬁrst episode of CM (cases), diagnosed by cerebrospinal
ﬂuid (CSF) India ink or cryptococcal antigen testing (titers
≥1:1024; Meridian Cryptococcal Latex Agglutination System,
Meridian Bioscience, Cincinnati, Ohio), who were enrolled
sequentially in 2 clinical trials examining different amphoteri-
cin B–based induction regimens [17, 18]. The studies were ap-
proved by the Research Ethics Committee of the University of
Cape Town, and patients gave informed consent for blood and
CSF samples to be used for research purposes. The component
trials had the same inclusion and exclusion criteria, and have
been described elsewhere [17, 18]. On study enrollment, history
and clinical examination ﬁndings were recorded. Blood samples
taken prior to antifungal therapy were used for plasma vitamin
D quantiﬁcation. Lumbar punctures (LPs) with quantitative
CSF cultures were performed on days 1, 3, 7, and 14. Cryptococ-
cal clearance (early fungicidal activity [EFA]) was calculated as
the rate of decrease in log colony-forming units (CFU) per mil-
liliter of CSF per day derived from the slope of the linear regres-
sion of log CFU per milliliter against time for each patient [19].
The CSF cell count and protein and glucose levels were deter-
mined. CSF interferon gamma (IFN-γ), tumor necrosis factor
alpha (TNF-α), and interleukin 6 (IL-6) concentrations were
measured in all patients using the Luminex multianalyte plat-
form (Luminex) and Bio-Rad cytokine kits (Bio-Rad) [20].
CSF soluble CD14 (sCD14) and neopterin concentrations
were measured for a subset of 90 sequential patients using
Bio-Rad kits and manual enzyme-linked immunosorbent
assay (ELItest Neopterin, BRAHMS Aktiengesellschaft, Hen-
nigsdorf, Germany), respectively. Baseline CD4 cell counts
were recorded for all patients. Patients were followed for 1
year and mortality outcomes recorded.
Recruited concurrently were 150 hospital-based control pa-
tients, who were HIV-infected adults (aged ≥21 years) with a
nadir CD4 count ≤100 cells/µL and no current evidence of or
prior history of cryptococcal disease, attending the hospital for
management of either newly diagnosed HIV infection or an op-
portunistic infection other than CM. These patients were drawn
from the same population as the cases during the same “risk pe-
riod,” and would have been included as a case in the study had
they developed CM. Basic demographic data, medical history,
and current CD4 count were recorded, and a blood sample was
taken for plasma vitamin D quantiﬁcation. Among cases and
controls, all patients currently taking antituberculosis medication
with a clinical diagnosis of tuberculosis (both sputum acid-fast
bacillus smear positive and smear negative) were deﬁned as hav-
ing active tuberculosis. Written informed consent was obtained
from each control participant, and the study was approved by
the Research Ethics Committee of the University of Cape Town.
Vitamin D Levels
Plasma 25(OH)D concentrations were measured in stored base-
line blood samples at St George’s University of London using
Immunodiagnostics Systems’ 25(OH)D kit (REF IS2700) on
the iSYS multidiscipline autoanalyzer. Vitamin D status was
deﬁned according to standard criteria as normal (>75 nmol/L),
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insufﬁcient (≤75 nmol/L), deﬁcient (≤50 nmol/L), or severely
deﬁcient (≤25 nmol/L) [13, 21].
Cryptococcal Meningitis Notiﬁcations
All incident laboratory-conﬁrmed cases of cryptococcal disease
from the Western Cape were reported to the NICD during the
study period with date of specimen collection; surveillance au-
dits were conducted to ensure complete reporting. A case of in-
cident cryptococcosis was deﬁned as the ﬁrst episode of
laboratory-conﬁrmed disease in a patient (encapsulated yeasts
observed by microscopic examination of an India ink–stained
ﬂuid, or a positive cryptococcal antigen test or culture of
Cryptococcus species from any body site) diagnosed at a clinical
laboratory in the Western Cape Province.
Statistical Analysis
Data were analyzed using Stata version 12.0 (StataCorp, College
Station, Texas), R version 3.0.2 (R foundation for Statistical Com-
puting), and GraphPad Prism version 6 (Graphpad Software Inc,
San Diego, California). Variables were compared across groups
using unpaired t tests, 1-way analysis of variance, Kruskal-Wallis,
χ2, or Fisher exact tests as appropriate. The 25(OH)D results were
log transformed, geometric means and 95% conﬁdence intervals
(CIs) presented, and log-transformed results used in regression
analyses. For the case-control analysis, crude and adjusted odds
ratios (ORs) exploring the association between vitamin D deﬁ-
ciency and CM, and potential confounders in this relationship,
were obtained using logistic regression analysis. Evidence for sea-
sonality in 25(OH) D levels and cryptococcal case notiﬁcations
was examined using Poisson regression models, which modeled
monthly data using a general trend plus a sinusoidal wave for sea-
sonal effect (cosinor regression modeling [22]). Assessment of
seasonality was made by comparing the Akaike information cri-
terion of models including or jointly omitting the sine and cosine
terms using a likelihood ratio test. Among the CM cases, associ-
ations between 25(OH)D levels and disease severity at presenta-
tion, baseline CSF immune responses, rate of clearance of
infection, and mortality were examined using linear and Cox re-
gression modeling. Statistical signiﬁcance was deﬁned as P≤ .05.
RESULTS
Demographic and clinical characteristics of patients are summa-
rized in Table 1. Patients with CM had a median CD4 count of
Table 1. Patient Characteristics and 25-Hydroxyvitamin D Levels
Characteristic CM Cases (n = 150) Controls (n = 150) Adjusted ORa P Value
Age, y 32 (28–38) 32 (27–37) .337
Male sex, % (No.) 41% (62) 17% (26) <.001
CD4 count, cells/µL 32 (13–58) 40 (19–79) .13
Active tuberculosis, % (No.) 35% (53) 42% (63) .236
On ART, % (No.) 0% (0) 30% (45) <.001
Duration of ART, d . . . 55 (21–99) . . .
Vitamin D, nmol/Lb 38 (35–41) 36 (33–39) .367
Vitamin D ≤75 nmol/L, % (No.) 93% (139) 95% (142) .338
Vitamin D ≤50 nmol/L, % (No.) 75% (112) 72% (108) .669
Vitamin D ≤25 nmol/L, % (No.) 18% (27) 26% (38) .116
Fungal burden, log1 0 CFU/mL 5.3 (4.3–5.8) . . . . . .
Altered mental status, % (No.) 13% (19) . . . . . .
EFA, log10 CFU/mL/d −0.52 (−0.39 to −0.69) . . . . . .
Mortalityc, % (No.) 28% (41) . . . . . .
Vitamin D >50 nmol/L, % (No.) 25% (38) 28% (41) 1 (base) .796
Vitamin D ≤50 nmol/L, % (No.) 75% (112) 72% (108) 0.93 (95% CI, .54–1.61)
Data presented are median (interquartile range) or percentage (No.). Significance testing was performed using Kruskal-Wallis, χ2, or Student t test as appropriate.
Abbreviations: ART, antiretroviral therapy; CFU, colony-forming units; CI, confidence interval; CM, cryptococcal meningitis; EFA, early fungicidal activity; OR, odds
ratio; vitamin D, 25-hydroxyvitamin D.
a Variables that were associated with both case status and vitamin D deficiency with a P value ≤0.1 were considered to be potential confounders in the relationship
between vitamin D deficiency and development of CM. The only variable meeting these criteria was season, which was adjusted for in the analysis reported here.
Levels of 25-hydroxyvitamin D varied by season, with the highest levels in the first quarter of the year (mean, 48 nmol/L [95% CI, 43–52 nmol/L]), lower levels in the
second quarter (mean, 33 nmol/L [95% CI, 29–38 nmol/L]), the lowest levels in the third quarter of the year (mean, 32 nmol/L [95% CI, 28–35 nmol/L]), and
increasing levels in the fourth quarter (mean, 38 nmol/L [95% CI, 34–42 nmol/L]), analysis of variance P = .005. Further adjustment for sex, CD4 count, and ART
status did not alter the findings (adjusted OR, 0.82 [95% CI, .44–1.51]; P = .523).
b Log-normal distribution; geometric mean and 95% CIs are presented.
c Mortality at 10 weeks.
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32 cells/µL, and severe disease at presentation, with high CSF
fungal burdens (median, 5.3 [interquartile range, 4.3–5.8 log10
CFU/mL]) and a high proportion of altered mental status
(13%). All CM patients were antiretroviral therapy (ART)
naive. The control patients were similar to cases in terms of
age and CD4 count, although a larger proportion was female,
and 30% were already taking ART. Sixty-three (42%) control pa-
tients had a current diagnosis of tuberculosis, compared with 53
(35%) of the CM cases (P = .24). Thirty-four (23%) controls had
advanced HIV infection alone, and the remaining 53 (35%) were
being investigated or treated for opportunistic infections or com-
plications of HIV infection (including 13 with gastroenteritis, 10
with pneumonia or bacterial sepsis, 6 with anemia, and 24 with
other conditions including Pneumocystis pneumonia, Kaposi
sarcoma, and candidiasis). All patients were black Africans.
Vitamin D Deﬁciency Is Common, and Clear Seasonal Variations
Are Observed
The mean 25(OH)D concentration of the total study population
(cases and controls combined) was 38 nmol/L (Figure 1). Only
18 (6%) had adequate 25(OH)D levels (>75 nmol/L). Two hun-
dred twenty (74%) had vitamin D deﬁciency (≤50 nmol/L), and
65 (22%) were severely vitamin D deﬁcient (≤25 nmol/L). Lev-
els of 25(OH)D varied by season, with the highest levels in the
ﬁrst quarter of the year (mean, 48 nmol/L [95% CI, 43–52
nmol/L]), corresponding to the southern hemisphere summer
and highest number of sunshine hours, and the lowest levels
in the third quarter of the year (mean, 32 nmol/L [95% CI,
28–35 nmol/L]), corresponding to the winter months and low-
est number of sunshine hours. Cosinor regression modeling
conﬁrmed the presence of signiﬁcant seasonality in vitamin D
levels (P < .001). The 25(OH)D levels did not differ by sex and
were not associated with age, CD4 count, or ART status.
No Seasonal Trends Are Evident in Cryptococcal Meningitis
Notiﬁcation Rates in the Western Cape Region
To examine associations between vitamin D status and the risk
of developing CM, the Western Cape region CM notiﬁcation
rates for the 7-year period 2005–2011 were analyzed for season-
al trends. Despite the seasonal variation in 25(OH)D levels seen
Figure 1. Plasma 25-hydroxyvitamin D (25[OH]D) levels by cryptococcal meningitis status, tuberculosis status, and season. A, Plasma 25(OH)D levels of
the whole study population (cases and controls combined), with dashed lines at 75 nmol/L (vitamin D insufﬁciency), 50 nmol/L (vitamin D deﬁciency), and
25 nmol/L (severe vitamin D deﬁciency). B and C, Plasma 25(OH)D levels according to cryptococcal meningitis case status (B) and tuberculosis status (C),
with lines at the geometric mean and error bars showing 95% conﬁdence intervals. Levels of 25(OH)D were signiﬁcantly lower in individuals with tuber-
culosis than in those without tuberculosis (*34 nmol/L vs 39 nmol/L; P = .029). D, Average number of sunshine hours per month in Cape Town (source:
National Oceanic and Atmospheric Administration, available at: www.noaa.gov). E, Levels of 25(OH)D by month (averaged over the 5-year study period) with
cosinor regression line. F, Monthly cryptococcal notiﬁcation rates (averaged over the period 2005–2011) with best-ﬁt regression line. Abbreviations: CM,
cryptococcal meningitis; TB, tuberculosis.
496 • CID 2014:59 (15 August) • Jarvis et al
in this patient population, cosinor regression modeling did not
demonstrate any seasonal trend in CM notiﬁcation rates
(P > .7), with an average of 39 cases per month during the pe-
riod and very little monthly variation (Figure 1).
Vitamin D Deﬁciency Is Not Associated With Cryptococcal
Meningitis, but Is Associated With Active Tuberculosis
Levels of 25(OH)D levels did not differ between CM cases and
control patients (mean, 38 nmol/L vs 36 nmol/L; P = .367;
Table 1). Vitamin D deﬁciency was not associated with CM
(OR, 1.12 [95% CI, .7–1.9]; P = .669), and this remained the
case in a multivariable logistic regression model adjusted for
season (adjusted OR [aOR], 0.93 [95% CI, .6–1.6]; P = .796).
A sensitivity analysis restricted to ART-naive patients yielded
the same ﬁndings (aOR, 0.82 [95% CI, .44–1.51]; P = .523), as
did the equivalent analysis looking at severe vitamin D deﬁ-
ciency (aOR, 0.62 [95% CI, .32–1.31]; P = .223). Conversely,
25(OH)D levels were lower in patients with active tuberculosis
compared with those without (34 nmol/L vs 39 nmol/L;
P = .029), and this difference remained signiﬁcant after adjust-
ing for CM case status and CD4 count (P = .04). In both CM
cases and controls, vitamin D deﬁciency was associated with in-
creased odds of active tuberculosis, with some evidence for an
increasing trend with worsening deﬁciency (OR, 1.47 [95% CI,
.5–4.7] for vitamin D insufﬁciency; OR, 1.51 [95% CI, .5–4.5]
for vitamin D deﬁciency; and OR, 2.52 [95% CI, .8–7.9] for
severe vitamin D deﬁciency, all compared to a baseline of
normal vitamin D status; P for trend = .069).
Vitamin D Status Is Not Associated With Disease Severity, Host
Immune Response, or Microbiological Clearance in Patients With
HIV-Associated Cryptococcal Meningitis
Among the 150 CM cases studied, there were no associations
between 25(OH)D level and either fungal burden at disease
presentation, the host immune response at the site of infection,
or the rate of clearance of infection (Figure 2 and Table 2).
Mean fungal burden was very similar in those with and without
vitamin D deﬁciency (5.1 log10 CFU/mL vs 5.0 log10 CFU/mL;
P = .687), as were CSF lymphocyte counts (15 × 106/L vs
19 × 106/L; P = .897), CSF TNF-α levels (0.84 log10 pg/mL vs
0.81 log10 pg/mL; P = .697), CSF IL-6 levels (2.44 log10 pg/mL
vs 2.28 log10 pg/mL; P = .540), and CSF IFN-γ levels (1.62
log10 pg/mL vs 1.61 log10 pg/mL; P = .988). Regression model-
ing conﬁrmed the absence of signiﬁcant associations between
25(OH)D levels and fungal burden, CSF lymphocytes, CSF
TNF-α levels, CSF IL-6 levels, and CSF IFN-γ levels (Table 2).
Given evidence that in the context of tuberculosis infection the
activation of macrophages by IFN-γ is vitamin D dependent
[11], we examined the ratio of IFN-γ to the macrophage activa-
tion markers sCD14 and neopterin. The IFN-γ:sCD14 ratios
(0.26 vs 0.25; P = .788) and IFN-γ:neopterin ratios (0.82 vs
0.83; P = .914) were similar in patients with and without vita-
min D deﬁciency, providing no evidence for differential macro-
phage activation in CM patients according to vitamin D status.
In keeping with the absence of any observed impact of vita-
min D status on the immune response to cryptococcal disease,
rates of clearance of Cryptococcus from the CSF were not asso-
ciated with 25(OH)D levels (β coefﬁcient −0.015 [95% CI,
−.09–.06]; P = .701). The mean rate of clearance was −0.56 in
those with vitamin D deﬁciency vs −0.56 in those without
(P = .847). Mortality at 10 weeks was 30% (n = 33) in patients
with vitamin D deﬁciency vs 22% (n = 8) in those without
(P = .367). After adjustment for CD4 count and the other key
predictors of mortality, baseline fungal burden and abnormal
mental status [23], the hazard of death was 1.35 (95% CI, .7–
2.6; P = .375) in vitamin D–deﬁcient patients compared with
those non–vitamin D–deﬁcient patients.
Figure 2. Fungal burden, cerebrospinal ﬂuid (CSF) immune responses, and rate of clearance of infection in cryptococcal meningitis patients with and
without vitamin D deﬁciency. The baseline CSF fungal burden (QCC), rate of clearance of infection (EFA), baseline CSF lymphocyte count, CSF TNF-α
concentration, and CSF IFN-γ concentration are shown according to whether patients were vitamin D deﬁcient ( plasma 25-hydroxyvitamin D
≤50 nmol/L). Lines indicate the mean in the vitamin D–deﬁcient patients and in those without vitamin D deﬁciency. No signiﬁcant differences were present
between the vitamin D–deﬁcient and –sufﬁcient groups in any of the variables shown. Abbreviations: CFU, colony-forming units; CSF, cerebrospinal ﬂuid;
EFA, early fungicidal activity; IFN, interferon; QCC, quantitative cryptococcal culture; TNF, tumor necrosis factor.
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DISCUSSION
Vitamin D deﬁciency was prevalent in this population of HIV-
infected black African patients in Cape Town, consistent with
previous ﬁndings in HIV-infected and uninfected populations
in this setting, and, in keeping with previous reports, showed
a marked seasonal variation closely related to sunshine exposure
[14]. Also consistent with recent studies from Cape Town [14]
was the observed association of vitamin D deﬁciency with active
tuberculosis. We did not ﬁnd any evidence for an association
between vitamin D status and either susceptibility to CM or
the immune response to CM and microbiological clearance in
patients who had developed CM. Levels of 25(OH)D levels did
not differ between the cohort of patients with CM and the con-
trol patients with comparable CD4 counts but no history of
cryptococcal disease. This remained the case in sensitivity anal-
ysis adjusting for ART status, the only important factor differ-
ing between the CM cases and controls. Further evidence for an
absence of association between vitamin D status and suscepti-
bility to CM was the lack of seasonal trend in CM notiﬁcations,
despite the clear seasonal variation in 25(OH)D levels in this
population [14]. Consistent with these observations were our
ﬁndings that vitamin D deﬁciency was not associated with fun-
gal burden at CM presentation, did not inﬂuence the CSF im-
mune response, and had no bearing on the rate at which
infection was cleared from the CSF. As in prior studies [14],
mean 25(OH)D levels in the studied population were low. Nev-
ertheless, variation within a range of relatively low levels was
associated with important differences in susceptibility to
tuberculosis in this and other studies [14], arguing against the
possibility that the lack of association seen with cryptococcal
disease was due to low population vitamin D status.
Very few prior studies have examined vitamin D in the con-
text of other fungal infections, and the reported results do not
show a consistent association with vitamin D status, which may
be related to the diverse host defense mechanisms involved
[24, 25]. Our ﬁndings suggest that immune control and clear-
ance of Cryptococcus is not via vitamin D–dependent pathways.
Given the immunomodulatory effects of vitamin D on both
innate and adaptive immunity [8–13, 26], plus reports demon-
strating impaired immune responses and increased susceptibil-
ity to HIV and HIV-associated opportunistic infections such as
tuberculosis, respiratory tract infections, and candidiasis [8, 9,
14, 26–28], the lack of any observed association with CM is per-
haps surprising. The bulk of the data concerning the role of
vitamin D in immunity to infectious diseases come from studies
of tuberculosis. Convincing evidence shows that vitamin D de-
ﬁciency is a risk factor for the development of tuberculosis
[14, 27, 28], and data from controlled trials suggest that vitamin
D replacement may improve outcomes in patients with tubercu-
losis [29].Macrophages from vitamin D–deﬁcient HIV-infected
patients demonstrate impaired intracellular signalling and
TNF-α expression in response to TLR2/4 signaling by MTB
[8], and these responses are restored by vitamin D supplemen-
tation in vitro. Activation of MTB-infected macrophages by T-
cell–derived IFN-γ is dependent on vitamin D [11], and can be
restored in macrophages from vitamin D–deﬁcient patients by
vitamin D supplementation. Importantly, for restriction of
Table 2. Associations Between Vitamin D Status and Fungal Burden, Immune Responses, and Rate of Clearance of Infection in Patients
With Cryptococcal Meningitis
Variable Vitamin D>50 nmol/L Vitamin D≤50 nmol/L P Value β Coefficienta P Value
Baseline fungal burden, log10 CFU/mL 5.0 (4.6–5.3) 5.1 (4.8–5.3) .687 0.07 (−.32 to .47) .702
CSF lymphocytes, ×106/Lb 19 (1–67) 15 (1–88) .896 −39 (−93 to 14) .148
CSF TNF-α, log10 pg/mL 0.81 (.70–.92) 0.84 (.76–0.92) .697 −0.09 (−.21 to .03) .148
CSF IFN-γ, log10 pg/mL 1.61 (1.41–1.81) 1.62 (1.49–1.74) .988 −0.09 (−.30 to .11) .374
CSF IL-6, log10 pg/mL 2.28 (1.84–2.72) 2.43 (2.19–2.69) .540 −0.26 (−.68 to .17) .231
CSF sCD14, log10 pg/mL 6.02 (5.91–6.11) 6.02 (5.97–6.09) .834 0.03 (−.07 to .12) .596
CSF neopterin, log10 pg/mL 1.85 (1.75–1.95) 1.90 (1.82–1.95) .522 −0.05 (−.16 to .06) .366
CSF IFN-γ:sCD14 ratio 0.25 (.21–.29) 0.26 (.23–.28) .788 −0.02 (−.05 to .02) .309
CSF IFN-γ:neopterin ratio 0.82 (.68–.97) 0.82 (.74–.90) .914 −0.04 (−.17 to .08) .497
Early fungicidal activity, log10 CFU/mL/d −0.56 (−0.46 to −0.66) −0.56 (−.51 to −0.60) .847 −0.02 (−.09 to .06) .701
Data are presented as means and 95% confidence intervals for the vitamin D–deficient and vitamin D–nondeficient groups.
Abbreviations: CFU, colony-forming units; CSF, cerebrospinal fluid; IFN, interferon; IL, interleukin; sCD14, soluble CD14; TNF, tumor necrosis factor; vitamin D, 25-
hydroxyvitamin D.
a The β coefficients are from linear regression analyses where the clinical and immunological parameters were considered individually as dependent variables, and
25-hydroxyvitamin D levels (log transformed) were considered as the explanatory variable. The coefficients shown thus represent the average increase in the
dependent variable for each single unit increase (log10 nmol/L) in 25-hydroxyvitamin D concentration.
b Heavily positively skewed; median values with interquartile ranges are shown.
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MTB growth in macrophages, vitamin D promotes phagolyso-
some fusion and maturation [9, 11], the generation of reactive
oxygen and nitrogen species [30, 31], production of antimicro-
bial cathelicidins [9, 11, 32], and induction of autophagy [9, 11].
These mechanisms overcome the immune evasion mechanisms
employed by MTB of blocking phagosome maturation, and
inhibiting phagosome-lysosome fusion [32–34]. In contrast to
MTB, Cryptococcus does not need to prevent phagosome mat-
uration or phagosome-lysosome fusion for intracellular surviv-
al, and is able to thrive in the acidic phagolysosome, protected
by a thick polysaccharide capsule and virulence factors such as
the ability to produce melanin using laccase, which protects
against the oxidative burst [2, 3]. It is thus probable that vitamin
D–dependent promotion of phagolysosome fusion and matura-
tion has little effect on anticryptococcal immunity. Similarly,
the promotion of cathelicidin production and autophagy,
neither of which have a proven role in the innate response to
cryptococcal infection [2], is unlikely to have signiﬁcant anti-
cryptococcal activity.
Activation of Cryptococcus-infected macrophages by T-cell–
derived IFN-γ is likely to be critical for effective control of cryp-
tococcal infection [35–37]. IFN-γ levels in the CSF are strongly
associated with fungal burden and the rate of fungal clearance in
patients with HIV-associated CM [20, 23], and exogenous IFN-γ
has been shown to signiﬁcantly increase the rate of clearance of
cryptococci from the CSF [18].Although we can only infer indi-
rectly from our results, we found no evidence to suggest that
IFN-γ–induced macrophage activation was vitamin D depen-
dent, unlike in IFN-γ–induced activation of MTB-infected mac-
rophages [11]. Levels of the macrophage activation markers
sCD14 and neopterin, and the IFN-γ:sCD14 and IFN-γ:neopter-
in ratios did not differ according to vitamin D status.
Interestingly, there are limited data to suggest that the protec-
tive effects of vitamin D in the host response to MTB are due to
anti-inﬂammatory properties, with inhibition of Th1-type im-
mune responses [38, 39], faster resolution of inﬂammation
[10], and limitation of the tissue damage associated with active
MTB infection [26, 40]. Again in contrast to tuberculosis, tissue
damage resulting from excessive inﬂammation is not a promi-
nent feature of HIV-associated CM [41]. Rather, a lack of Th1-
type inﬂammatory responses and high organism burdens are
associated with poor outcomes in HIV-associated CM [18, 23,
37, 42], underlining the differing immune responses required
for effective control of the opportunistic intracellular pathogens
MTB and Cryptococcus.
In summary, we found no evidence that vitamin D deﬁciency
predisposes to the development of CM, or leads to impaired im-
mune responses or microbiological clearance in HIV-infected
patients with CM. These data suggest that, in contrast to tuber-
culosis, vitamin D–dependent pathways are not of key impor-
tance in the host immune response to cryptococcal infection.
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